Anktiva

ImmunityBio faces securities lawsuit after FDA warns of misleading Anktiva efficacy claims. Stock plunges 21%, erasing $2B in market value.

ImmunityBio faces securities fraud lawsuit following FDA warning letter about Anktiva cancer therapy misleading ads. Stock plummeted to $7.42.

ImmunityBio ($IBRX) shares plunged 21% after FDA warning over false Anktiva efficacy claims, erasing $2 billion in market value and triggering securities litigation.

ImmunityBio shares plunge 21% after FDA warning over unsupported cancer treatment claims, erasing $2 billion in market value and triggering securities litigation.

Class action lawsuit filed against ImmunityBio for allegedly making false statements about cancer treatment Anktiva. FDA issued warning letter; stock fell 21% after disclosure.

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.

ImmunityBio shares surge 10.6% after completing NK cell manufacturing programs producing five billion cells safely, plus FDA acknowledges ANKTIVA resubmission for bladder cancer.

ImmunityBio completed Phase 3 cancer trial enrollment ahead of schedule with strong 85% response rates. Anktiva sales surged 750% year-over-year, hitting $38.29M in revenue.

ImmunityBio launches 85-person European sales team for bladder cancer drug Anktiva across 30 countries, partnering with Accord Healthcare and establishing an Irish subsidiary for distribution.

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.